Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ashim Gupta

Showing results (111-120 of 129) with videos related to

Pageof 13
Sort By:
Clinical and Experimental Psychology|June 26, 2023
Beyond Mor: Can Induction of Dopamine Homeostasis Along with Electrotherapy Attenuate the Opioid Crisis?Kenneth Blum, Abdalla Bowirrat, Eric R Braverman, et al.
Journal of Personalized Medicine|December 29, 2022
Genetic Addiction Risk Severity Assessment Identifies Polymorphic Reward Genes as Antecedents to Reward Deficiency Syndrome (RDS) Hypodopaminergia's Effect on Addictive and Non-Addictive Behaviors in a Nuclear FamilyCatherine A Dennen, Kenneth Blum, Abdalla Bowirrat, et al.
Journal of Personalized Medicine|December 23, 2022
Theorizing the Role of Dopaminergic Polymorphic Risk Alleles with Intermittent Explosive Disorder (IED), Violent/Aggressive Behavior and Addiction: Justification of Genetic Addiction Risk Severity (GARS) TestingEdward Justin Modestino, Kenneth Blum, Catherine A Dennen, et al.
Journal of Personalized Medicine|October 27, 2022
Should Reward Deficiency Syndrome (RDS) Be Considered an Umbrella Disorder for Mental Illness and Associated Genetic and Epigenetic Induced Dysregulation of Brain Reward Circuitry?Kenneth Blum, Catherine A Dennen, Igor Elman, et al.
Journal of Personalized Medicine|September 23, 2022
Statistical Validation of Risk Alleles in Genetic Addiction Risk Severity (GARS) Test: Early Identification of Risk for Alcohol Use Disorder (AUD) in 74,566 Case-Control SubjectsKenneth Blum, David Han, Ashim Gupta, et al.
Journal of Personalized Medicine|December 29, 2022
Genetic Addiction Risk and Psychological Profiling Analyses for "Preaddiction" Severity IndexKenneth Blum, David Han, Abdalla Bowirrat, et al.
Journal of the Neurological Sciences|September 9, 2022
Why haven't we solved the addiction crisis?Kenneth Blum, Abdalla Bowirrat, Luis Llanos Gomez, et al.
Journal of Personalized Medicine|December 23, 2022
Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent OpioidsMauro Ceccanti, Kenneth Blum, Abdalla Bowirrat, et al.
Journal of Personalized Medicine|June 24, 2022
Researching Mitigation of Alcohol Binge Drinking in Polydrug Abuse: KCNK13 and RASGRF2 Gene(s) Risk Polymorphisms Coupled with Genetic Addiction Risk Severity (GARS) Guiding Precision Pro-Dopamine RegulationKenneth Blum, Mark S Brodie, Subhash C Pandey, et al.
Journal of Personalized Medicine|February 25, 2022
Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It "Blowin' in the Wind"?Kenneth Blum, Thomas McLaughlin, Abdalla Bowirrat, et al.
Pageof 13

Showing results (111-120 of 129) with videos related to

Sort By:
Pageof 13
Clinical and Experimental Psychology|June 26, 2023
Beyond Mor: Can Induction of Dopamine Homeostasis Along with Electrotherapy Attenuate the Opioid Crisis?Kenneth Blum, Abdalla Bowirrat, Eric R Braverman, et al.
Journal of Personalized Medicine|December 29, 2022
Genetic Addiction Risk Severity Assessment Identifies Polymorphic Reward Genes as Antecedents to Reward Deficiency Syndrome (RDS) Hypodopaminergia's Effect on Addictive and Non-Addictive Behaviors in a Nuclear FamilyCatherine A Dennen, Kenneth Blum, Abdalla Bowirrat, et al.
Journal of Personalized Medicine|December 23, 2022
Theorizing the Role of Dopaminergic Polymorphic Risk Alleles with Intermittent Explosive Disorder (IED), Violent/Aggressive Behavior and Addiction: Justification of Genetic Addiction Risk Severity (GARS) TestingEdward Justin Modestino, Kenneth Blum, Catherine A Dennen, et al.
Journal of Personalized Medicine|October 27, 2022
Should Reward Deficiency Syndrome (RDS) Be Considered an Umbrella Disorder for Mental Illness and Associated Genetic and Epigenetic Induced Dysregulation of Brain Reward Circuitry?Kenneth Blum, Catherine A Dennen, Igor Elman, et al.
Journal of Personalized Medicine|September 23, 2022
Statistical Validation of Risk Alleles in Genetic Addiction Risk Severity (GARS) Test: Early Identification of Risk for Alcohol Use Disorder (AUD) in 74,566 Case-Control SubjectsKenneth Blum, David Han, Ashim Gupta, et al.
Journal of Personalized Medicine|December 29, 2022
Genetic Addiction Risk and Psychological Profiling Analyses for "Preaddiction" Severity IndexKenneth Blum, David Han, Abdalla Bowirrat, et al.
Journal of the Neurological Sciences|September 9, 2022
Why haven't we solved the addiction crisis?Kenneth Blum, Abdalla Bowirrat, Luis Llanos Gomez, et al.
Journal of Personalized Medicine|December 23, 2022
Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent OpioidsMauro Ceccanti, Kenneth Blum, Abdalla Bowirrat, et al.
Journal of Personalized Medicine|June 24, 2022
Researching Mitigation of Alcohol Binge Drinking in Polydrug Abuse: KCNK13 and RASGRF2 Gene(s) Risk Polymorphisms Coupled with Genetic Addiction Risk Severity (GARS) Guiding Precision Pro-Dopamine RegulationKenneth Blum, Mark S Brodie, Subhash C Pandey, et al.
Journal of Personalized Medicine|February 25, 2022
Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It "Blowin' in the Wind"?Kenneth Blum, Thomas McLaughlin, Abdalla Bowirrat, et al.
Pageof 13